Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
We haven't written up this one. NPR Health has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.

